Last10K.com

Alexion Pharmaceuticals Inc (ALXN) SEC Filing 10-K Annual report for the fiscal year ending Sunday, December 31, 2017

SEC Filings

ALXN Valuations

Intrinsic Value
Financial Stability
Financial Ratios
Insider Trades
Manager Portfolios
Notifications

ALXN Annual Reports

ALXN Quarterly Reports

ALXN Corporate News

ALXN Merger Prospectus

Alexion Pharmaceuticals, Inc.

HISTORY TOOLS
CIK: 899866 Ticker: ALXN




a2016earningsreleaseimagea05.jpg
Alexion Reports Fourth Quarter and Full Year 2017 Results and Provides Financial Guidance for 2018

•
2017 Total Revenues of $3.551 Billion, a 15 Percent Increase Over 2016 and a 17 Percent Volume Increase

•
2017 GAAP Diluted EPS of $1.97 Per Share, a 12 Percent Increase Over 2016; Non-GAAP Diluted EPS of $5.86 Per Share, a 27 Percent Increase Over 2016

•
Continued Double-Digit Volume Growth of Soliris in 2017 Despite Rapid Enrollment in ALXN1210 Trials

•
Initial Launches Underway for Soliris in Patients with AchR Antibody-Positive Generalized Myasthenia Gravis (gMG) in the U.S., Germany and Japan

•
Data from ALXN1210 Phase 3 PNH Naive and Switch Studies Expected in Second Quarter of 2018

•
Four New Independent Directors With Deep Biopharmaceutical Experience Appointed to Alexion's Board of Directors

•
2018 Guidance: Revenue $3.850 to $3.950 Billion; GAAP Diluted EPS $4.35 to $4.75 Per Share; Non-GAAP Diluted EPS $6.60 to $6.80 Per Share

NEW HAVEN, Conn., February 8, 2018- Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) today announced financial results for the fourth quarter and full year of 2017. Total revenues for the full year of 2017 were $3.551 billion, a 15 percent increase compared to 2016. The negative impact of foreign currency on total revenues year-over-year was 1 percent or $28.6 million, net of hedging activities. On a GAAP basis, diluted earnings per share (EPS) for the full year of 2017 was $1.97, a 12 percent increase versus the prior year, inclusive of $286.5 million of expenses related to the previously announced restructuring activities. Non-GAAP diluted EPS for the full year of 2017 was $5.86 per share, a 27 percent increase versus the prior year.

Total revenues in the fourth quarter were $909.7 million, a 9.5 percent increase compared to the same period in 2016. The benefit of foreign currency on total revenues year-over-year was less than 1 percent or $0.1 million, net of hedging activities. On a GAAP basis, diluted EPS in the quarter was $0.13 per share, a 68 percent decrease versus the prior year, inclusive of $95.1 million of expenses related to the previously announced restructuring activities and $45.8 million related to U.S. tax reform. Non-GAAP diluted EPS for the fourth quarter of 2017 was $1.48 per share, a 17 percent increase versus the prior year.

"2017 was a year of rapid transformation for Alexion as we continued to advance our global leadership in rare diseases and position Alexion for the future. I am proud of our accomplishments and performance in 2017, which include strengthening the leadership team and Board of Directors, achieving regulatory


The following information was filed by Alexion Pharmaceuticals, Inc. (ALXN) on Thursday, February 8, 2018 as an 8K 2.02 statement, which is an earnings press release pertaining to results of operations and financial condition. It may be helpful to assess the quality of management by comparing the information in the press release to the information in the accompanying 10-K Annual Report statement of earnings and operation as management may choose to highlight particular information in the press release.

View differences made from one year to another to evaluate Alexion Pharmaceuticals, Inc.'s financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 10-K Annual Report to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Alexion Pharmaceuticals, Inc..

Continue

Assess how Alexion Pharmaceuticals, Inc.'s management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Alexion Pharmaceuticals, Inc.'s Definitive Proxy Statement (Form DEF 14A) filed after their 2018 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors

Continue

SEC Filing Tools

Rating

Learn More
Bullish Bearish Neutral
Filter Sentiment:
All
Positive
Negative
Filter Category:
All
Financial
Legal
Revenue
M & A
Other
Filter Subcategory:
All
Cash Flow
Earnings
Expense
Debt
Shares
Geography
Product
Other
Inside Alexion Pharmaceuticals, Inc.'s 10-K Annual Report:

Financial Statements, Disclosures and Schedules

Inside this 10-K Annual Report

Document And Entity Information Document
Consolidated Balance Sheets
Consolidated Balance Sheets (parenthetical)
Consolidated Statement Of Comprehensive Income
Consolidated Statement Of Comprehensive Income (parentheticals)
Consolidated Statements Of Operations
Statement Of Cash Flows
Statement Of Shareholders' Equity
Accrued Expenses
Accrued Expenses (schedule Of Accrued Expenses) (details)
Accrued Expenses (tables)
Acquisitions
Acquisitions (acquisition Related Costs) (details)
Acquisitions (narrative) (details)
Acquisitions (pro Forma Financial Information Of Combined Results Of Operations) (details)
Acquisitions (purchase Price Allocation To Assets Acquired And Liabilities Assumed) (details)
Acquisitions (reconciliation Of Upfront Payments To Total Purchase Price) (details)
Acquisitions (tables)
Business Overview And Summary Of Significant Accounting Policies
Business Overview And Summary Of Significant Accounting Policies (earnings Per Common Share) (details)
Business Overview And Summary Of Significant Accounting Policies (inventories) (details)
Business Overview And Summary Of Significant Accounting Policies (narrative) (details)
Business Overview And Summary Of Significant Accounting Policies (policies)
Business Overview And Summary Of Significant Accounting Policies (tables)
Commitments And Contingencies
Commitments And Contingencies (narrative) (details)
Commitments And Contingencies (schedule Of Aggregate Future Minimum Annual Rental Payments) (details)
Commitments And Contingencies (tables)
Debt
Debt (details)
Debt - Schedule Of Maturities Of Long-term Debt (details)
Debt Debt (tables)
Derivative Instruments And Hedging Activities
Derivative Instruments And Hedging Activities (narrative) (details)
Derivative Instruments And Hedging Activities (schedule Of Fair Value Of Outstanding Derivatives) (details)
Derivative Instruments And Hedging Activities (schedule Of Offsetting Assets And Liabilities) (details)
Derivative Instruments And Hedging Activities (schedule Of Other Comprehensive Income And Earnings From Foreign Exchange Contracts) (details)
Derivative Instruments And Hedging Activities (tables)
Employee Benefit Plans
Employee Benefit Plans (narrative) (details)
Employee Benefit Plans (schedule Of Change In Benefit Obligation) (details)
Employee Benefit Plans (schedule Of Change In Plan Assets) (details)
Employee Benefit Plans (schedule Of Components Of Net Periodic Benefit Cost) (details)
Employee Benefit Plans (schedule Of Estimated Future Benefit Payments) (details)
Employee Benefit Plans (schedule Of Fair Value Of Plan Assets) (details)
Employee Benefit Plans (schedule Of Other Changes In Plan Assets And Benefit Obligations Recognized In Other Comprehensive Income) (details)
Employee Benefit Plans (schedule Of Weighted Average Assumptions Used To Calculate Net Periodic Benefit Cost And The Actuarial Present Value Of Projected Benefit Obligations) (details)
Employee Benefit Plans (tables)
Facility Lease Obligations
Facility Lease Obligations (details)
Facility Lease Obligations (tables)
Facility Lease Obligations - Aggregate Future Minimum Non-cancellable Commitments Under Facility Lease Obligation (details)
Fair Value Measurement
Fair Value Measurement (schedule Of Acquisition-related Contingent Consideration) (details)
Fair Value Measurement (schedule Of Assets And Liabilites Measured At Fair Value) (details)
Fair Value Measurement (tables)
Income Taxes
Income Taxes (narrative) (details)
Income Taxes (reconciliation Of The Statutory U.s. Federal Income Tax Rate To Effective Income Tax Rate) (details)
Income Taxes (reconciliation Of Unrecognized Tax Benefits) (details)
Income Taxes (schedule Of Components Of Deferred Tax Assets And Liabilities) (details)
Income Taxes (schedule Of Components Of Income Tax Provision (benefit)) (details)
Income Taxes (schedule Of Income Tax Provision (benefit) On Income Before Income Taxes) (details)
Income Taxes (tables)
Intangible Assets And Goodwill
Intangible Assets And Goodwill (schedule Of Changes In The Carrying Amount Of Goodwill) (details)
Intangible Assets And Goodwill (schedule Of Intangible Assets And Goodwill) (details)
Intangible Assets And Goodwill (tables)
Intangible Assets And Goodwill Narratives (details)
Marketable Securities
Marketable Securities (available-for-sale Debt Securities By Contractual Maturity) (details)
Marketable Securities (available-for-sale Securities By Classification In Balance Sheet) (details)
Marketable Securities (narrative) (details)
Marketable Securities (summary Of Avaiable-for-sale Securities Held) (details)
Marketable Securities (tables)
Other Comprehensive Income And Accumulated Other Comprehensive Income (notes)
Other Comprehensive Income And Accumulated Other Comprehensive Income (reclassifications Out Of Accumulated Other Comprehensive Income) (details)
Other Comprehensive Income And Accumulated Other Comprehensive Income (schedule Of Accumulated Other Comprehensive Income (loss)) (details)
Other Comprehensive Income And Accumulated Other Comprehensive Income (tables)
Property, Plant And Equipment, Net
Property, Plant And Equipment, Net (details)
Property, Plant And Equipment, Net (tables)
Quarterly Financial Information (unaudited)
Quarterly Financial Information (unaudited) (details)
Quarterly Financial Information (unaudited) (tables)
Restructuring (tables)
Restructuring And Related Expenses
Restructuring And Related Expenses (details)
Restructuring And Related Expenses - Reconciliation Of Restructuring Reserve (details)
Segment Information
Segment Information (details)
Segment Information (tables)
Segment Information - Net Product Sales (details)
Share-based Compensation
Share-based Compensation (narrative) (details)
Share-based Compensation (schedule Of Components Of Allocated Share-based Compensation Expense And Capitalization Of Share Based Compensation Expense) (details)
Share-based Compensation (schedule Of Ranges Of Weighted Average Assumptions) (details)
Share-based Compensation (schedule Of Status Of Non-vested Restricted Stock) (details)
Share-based Compensation (schedule Of Status Of Stock Option Plans) (details)
Share-based Compensation (tables)
Stockholders' Equity
Stockholders' Equity (details)
Ticker: ALXN
CIK: 899866
Form Type: 10-K Annual Report
Accession Number: 0000899866-18-000022
Submitted to the SEC: Thu Feb 08 2018 4:26:33 PM EST
Accepted by the SEC: Thu Feb 08 2018
Period: Sunday, December 31, 2017
Industry: Pharmaceutical Preparations

External Resources:
Stock Quote
Social Media

Bookmark the Permalink:
https://last10k.com/sec-filings/alxn/0000899866-18-000022.htm